Aptevo Therapeutics (Nasdaq: APVO) reported a striking 85% remission rate with its bispecific antibody mipletamig in unfit frontline AML patients, showing superiority over venetoclax/azacitidine alone. With no dose-limiting toxicities or cytokine release syndrome observed, mipletamig is emerging as a potentially transformative CD123 x CD3 therapy poised to reshape the frontline AML treatment landscape.

Processa Pharmaceuticals (Nasdaq: PCSA) has signed a binding term sheet granting Intact Therapeutics exclusive rights to license PCS12852, a Phase 2-ready 5-HT4 agonist targeting gastroparesis. The deal includes $2.5M in near-term payments, potential milestones totaling over $452.5M, double-digit royalties, and a 3.5% equity stake—indicating significant commercial potential in a high-need GI market.

Brag House (NASDAQ: TBH) is launching a revenue-generating platform enabling NCAA athletes to monetize their Name, Image, and Likeness (NIL) through personalized digital assets. With reach across 200+ campuses and a smart contract-based system, the company is tapping into the projected $1.5B NIL market while creating scalable, high-margin revenue streams tied to Gen Z engagement and digital ownership.

Lantern Pharma (Nasdaq: LTRN) announced a remarkable complete response in a heavily pre-treated never-smoker with advanced NSCLC enrolled in its HARMONIC trial of LP-300, with survival benefits continuing nearly two years. This durable, tumor-erasing outcome—achieved after failure of three prior therapies—reinforces LP-300’s potential to address the $4B+ global market for lung cancer in never-smokers, a growing and underserved patient population with no approved options post-kinase inhibitor therapy.